
Theodore M. Blum
Examiner (ID: 8545)
| Most Active Art Unit | 2202 |
| Art Unit(s) | 2202, 2200, 2604, 3662, 2607, 3642, 2603 |
| Total Applications | 2205 |
| Issued Applications | 1954 |
| Pending Applications | 86 |
| Abandoned Applications | 165 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18522180
[patent_doc_number] => 20230232828
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => SULPHONAMIDES AS METHIONINE METABOLIC PATHWAY INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/130619
[patent_app_country] => US
[patent_app_date] => 2023-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10403
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 697
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18130619
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/130619 | SULPHONAMIDES AS METHIONINE METABOLIC PATHWAY INHIBITORS | Apr 3, 2023 | Abandoned |
Array
(
[id] => 18567049
[patent_doc_number] => 20230257378
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => POLYMORPHS OF THE HYDROCHLORIDE SALT OF LINAPRAZAN GLURATE
[patent_app_type] => utility
[patent_app_number] => 18/130245
[patent_app_country] => US
[patent_app_date] => 2023-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9950
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18130245
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/130245 | Polymorphs of the hydrochloride salt of linaprazan glurate | Apr 2, 2023 | Issued |
Array
(
[id] => 18748344
[patent_doc_number] => 11807640
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-11-07
[patent_title] => 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as anti-tubercular agents
[patent_app_type] => utility
[patent_app_number] => 18/191407
[patent_app_country] => US
[patent_app_date] => 2023-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7865
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191407
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/191407 | 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as anti-tubercular agents | Mar 27, 2023 | Issued |
Array
(
[id] => 19202762
[patent_doc_number] => 20240174661
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/190920
[patent_app_country] => US
[patent_app_date] => 2023-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42423
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18190920
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/190920 | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors | Mar 26, 2023 | Issued |
Array
(
[id] => 18575457
[patent_doc_number] => 11731970
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-08-22
[patent_title] => Pyrrolo[2,3-b]quinoline compounds as antibacterial agents
[patent_app_type] => utility
[patent_app_number] => 18/125262
[patent_app_country] => US
[patent_app_date] => 2023-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10163
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18125262
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/125262 | Pyrrolo[2,3-b]quinoline compounds as antibacterial agents | Mar 22, 2023 | Issued |
Array
(
[id] => 18484833
[patent_doc_number] => 20230212140
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => GLP-1 RECEPTOR AGONIST AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/120876
[patent_app_country] => US
[patent_app_date] => 2023-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18120876
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/120876 | GLP-1 receptor agonist and use thereof | Mar 12, 2023 | Issued |
Array
(
[id] => 19701452
[patent_doc_number] => 12195461
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => Pyrrolo-dipyridine compounds
[patent_app_type] => utility
[patent_app_number] => 18/179818
[patent_app_country] => US
[patent_app_date] => 2023-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 23876
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18179818
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/179818 | Pyrrolo-dipyridine compounds | Mar 6, 2023 | Issued |
Array
(
[id] => 20049814
[patent_doc_number] => 20250188036
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-12
[patent_title] => A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE
[patent_app_type] => utility
[patent_app_number] => 18/842194
[patent_app_country] => US
[patent_app_date] => 2023-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13923
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18842194
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/842194 | A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE | Mar 5, 2023 | Pending |
Array
(
[id] => 18451410
[patent_doc_number] => 20230192688
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/110259
[patent_app_country] => US
[patent_app_date] => 2023-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20716
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 300
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18110259
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/110259 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | Feb 14, 2023 | Issued |
Array
(
[id] => 18649363
[patent_doc_number] => 20230295161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/107979
[patent_app_country] => US
[patent_app_date] => 2023-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18107979
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/107979 | Methods and compositions for treating polycystic ovary syndrome | Feb 8, 2023 | Issued |
Array
(
[id] => 18435944
[patent_doc_number] => 20230183238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/164443
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -96
[patent_words_short_claim] => 4
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164443
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/164443 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Feb 2, 2023 | Abandoned |
Array
(
[id] => 18537436
[patent_doc_number] => 20230242528
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOME
[patent_app_type] => utility
[patent_app_number] => 18/160594
[patent_app_country] => US
[patent_app_date] => 2023-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19781
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 354
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18160594
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/160594 | N-oxide inhibitors of NLRP3 inflammasome | Jan 26, 2023 | Issued |
Array
(
[id] => 19769853
[patent_doc_number] => 20250051279
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => TRYPTAMINE COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 18/720922
[patent_app_country] => US
[patent_app_date] => 2023-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62616
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18720922
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/720922 | TRYPTAMINE COMPOSITIONS AND METHODS | Jan 12, 2023 | Pending |
Array
(
[id] => 19325964
[patent_doc_number] => 12043629
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-23
[patent_title] => RIP1K inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/154255
[patent_app_country] => US
[patent_app_date] => 2023-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23449
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154255
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/154255 | RIP1K inhibitors | Jan 12, 2023 | Issued |
Array
(
[id] => 18725756
[patent_doc_number] => 20230339964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/152049
[patent_app_country] => US
[patent_app_date] => 2023-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47891
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152049
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/152049 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | Jan 8, 2023 | Abandoned |
Array
(
[id] => 18484857
[patent_doc_number] => 20230212166
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE
[patent_app_type] => utility
[patent_app_number] => 18/089498
[patent_app_country] => US
[patent_app_date] => 2022-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18089498
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/089498 | SUBSTITUTED NAPHTHALENE DIIMIDES AND THEIR USE | Dec 26, 2022 | Abandoned |
Array
(
[id] => 19769859
[patent_doc_number] => 20250051285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => CRYSTALLINE SALT FORM OF EP4 ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 18/719032
[patent_app_country] => US
[patent_app_date] => 2022-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4610
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18719032
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/719032 | CRYSTALLINE SALT FORM OF EP4 ANTAGONIST | Dec 21, 2022 | Pending |
Array
(
[id] => 19784149
[patent_doc_number] => 20250057828
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA
[patent_app_type] => utility
[patent_app_number] => 18/722233
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15520
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 415
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18722233
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/722233 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Dec 19, 2022 | Pending |
Array
(
[id] => 18524267
[patent_doc_number] => 20230234924
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4
[patent_app_type] => utility
[patent_app_number] => 18/084245
[patent_app_country] => US
[patent_app_date] => 2022-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18084245
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/084245 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | Dec 18, 2022 | Issued |
Array
(
[id] => 18675034
[patent_doc_number] => 20230312585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE
[patent_app_type] => utility
[patent_app_number] => 18/068005
[patent_app_country] => US
[patent_app_date] => 2022-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36363
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068005
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/068005 | Substituted 4-phenylpiperidines, their preparation and use | Dec 18, 2022 | Issued |